



## Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 24, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2026-- [Amylyx Pharmaceuticals, Inc.](#) (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Amylyx’s senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.

To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, <https://investors.amylyx.com/events-presentations>. The webcast will be archived and available for replay for 90 days following the event.

### About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe they can make the greatest impact. For more information, visit [amylyx.com](https://amylyx.com) and follow us on [LinkedIn](#) and [X](#). For investors, please visit [investors.amylyx.com](https://investors.amylyx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260224052667/en/): <https://www.businesswire.com/news/home/20260224052667/en/>

#### Media

Amylyx Media Team  
+1 (857) 320-6191  
[amylyxmediateam@amylyx.com](mailto:amylyxmediateam@amylyx.com)

#### Investors

Lindsey Allen  
Amylyx Pharmaceuticals, Inc.  
+1 (857) 320-6244  
[Investors@amylyx.com](mailto:Investors@amylyx.com)

Source: Amylyx Pharmaceuticals, Inc.